D
Dwight H. Owen
Researcher at Ohio State University
Publications - 143
Citations - 2055
Dwight H. Owen is an academic researcher from Ohio State University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 75 publications receiving 941 citations. Previous affiliations of Dwight H. Owen include Memorial Sloan Kettering Cancer Center & The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
Oliver Gautschi,Julie Milia,Thomas Filleron,Juergen Wolf,David P. Carbone,Dwight H. Owen,R. Camidge,Vignhesh Narayanan,Robert C. Doebele,Benjamin Besse,Jordi Remon-Masip,Pasi A. Jänne,Mark M. Awad,Nir Peled,Chul Cho Byoung,Daniel D. Karp,Michael Van Den Heuvel,Heather A. Wakelee,Joel W. Neal,Tony Mok,James Chih-Hsin Yang,Sai-Hong Ignatius Ou,Georg Pall,Patrizia Froesch,Gérard Zalcman,David R. Gandara,Jonathan W. Riess,Vamsidhar Velcheti,Kristin Zeidler,Joachim Diebold,Martin Früh,Sebastian Michels,Isabelle Monnet,Sanjay Popat,Rafael Rosell,Niki Karachaliou,Sacha I. Rothschild,Jin-Yuan Shih,Arne Warth,Thomas Muley,Florian Cabillic,Julien Mazieres,Alexander Drilon +42 more
TL;DR: The results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to the authors' knowledge, on outcomes of RET-directed therapy thus far, are presented.
Journal ArticleDOI
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Bairavi Shankar,Jiajia Zhang,Abdul Rafeh Naqash,Patrick M. Forde,Josephine Feliciano,Kristen A. Marrone,David S. Ettinger,Christine L. Hann,Julie R. Brahmer,Biagio Ricciuti,Biagio Ricciuti,Dwight H. Owen,Yukihiro Toi,Paul R. Walker,Gregory A. Otterson,Sandip H. Patel,Shunichi Sugawara,Jarushka Naidoo,Jarushka Naidoo +18 more
TL;DR: Development of multisystem irAEs was associated with improved survival in patients with advanced NSCLC treated with ICIs, and this multicenter cohort study carried out in 5 academic institutions worldwide found.
Journal ArticleDOI
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Hamzah Abu-Sbeih,David Faleck,Biagio Ricciuti,Biagio Ricciuti,Robin B. Mendelsohn,Abdul Rafeh Naqash,Justine V. Cohen,MacLean C. Sellers,Aanika Balaji,Guy Ben-Betzalel,Ibraheim Hajir,Jiajia Zhang,Mark M. Awad,Giulia Costanza Leonardi,Giulia Costanza Leonardi,Douglas B. Johnson,David J. Pinato,Dwight H. Owen,Sarah A. Weiss,Giuseppe Lamberti,Mark P. Lythgoe,Lisa Manuzzi,Christina A. Arnold,Wei Qiao,Jarushka Naidoo,Gal Markel,Nick Powell,Sai Ching J. Yeung,Elad Sharon,Michael Dougan,Yinghong Wang +30 more
TL;DR: Preexisting IBD increases the risk of severeGI adverse events in patients treated with immune checkpoint inhibitors, and anti–cytotoxic T-lymphocyte antigen-4 therapy was associated with increased risk of GI adverse events.
Journal ArticleDOI
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Hamzah Abu-Sbeih,Faisal Ali,Abdul Rafeh Naqash,Dwight H. Owen,Sandipkumar Patel,Gregory A. Otterson,Kari Kendra,Biagio Ricciuti,Rita Chiari,Andrea De Giglio,Joseph Sleiman,Pauline Funchain,Beatriz Wills,Jiajia Zhang,Jarushka Naidoo,Jessica Philpott,Jianjun Gao,Sumit K. Subudhi,Yinghong Wang +18 more
TL;DR: One third of patients who resumed ICI treatment after IMDC experienced recurrent IMDC, and recurrence of IMDC was less frequent after resuming of anti–PD-1/L1 than after resumption of anti-CTLA-4.
Journal ArticleDOI
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers
Alexander Drilon,Alexander Drilon,Jessica J. Lin,Thomas Filleron,Ai Ni,Julie Milia,Isabella Bergagnini,Vaios Hatzoglou,Vamsidhar Velcheti,M. Offin,M. Offin,Bob T. Li,Bob T. Li,David P. Carbone,Benjamin Besse,Tony Mok,Mark M. Awad,Jürgen Wolf,Dwight H. Owen,D. Ross Camidge,Gregory J. Riely,Gregory J. Riely,Nir Peled,Mark G. Kris,Mark G. Kris,Julien Mazieres,Justin F. Gainor,Oliver Gautschi +27 more
TL;DR: Brain metastases occur frequently in RET‐rearranged lung cancers, and outcomes with multikinase inhibitor therapy in general are suboptimal.